A team of researchers investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.
Jul 24, 2020
0
2
CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical ...
Jul 23, 2020
0
3
(HealthDay)—Lymphoma survivors are at substantial long-term risk for chronic kidney disease (CKD) development, according to a study published online July 11 in Leukemia & Lymphoma.
Jul 20, 2020
0
10
A general problem encountered in cancer therapy is that many patients develop resistance to a drug over the course of treatment. In the case of the blood cancer anaplastic large cell lymphoma (ALCL), an international team ...
Jul 15, 2020
0
0
(HealthDay)—The incidence of venous thromboembolism (VTE) and major bleeding is high among patients with primary central nervous system lymphoma (PCNSL), according to a study published online June 23 in Leukemia & Lymphoma.
Jun 29, 2020
0
3
The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published today in the New England Journal of Medicine. This academic trial involved two international cooperative groups—the ...
Jun 4, 2020
0
1
Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated ...
Jun 4, 2020
0
0
(HealthDay)—For adolescent and young adult (AYA) patients with Hodgkin lymphoma (HL), treatment strategies differ, but outcomes are equivalent with treatment at pediatric and adult centers, according to a study published ...
May 29, 2020
0
2
Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma
May 26, 2020
0
5
A research team led by Hong Kong Baptist University (HKBU) has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumors caused by ...
May 11, 2020
0
8
